New Haven, Connecticut

New Haven, Connecticut 06520

0 studies enrolling now · 7 studies all time

What they study most

Alopecia Areata, Apathy in Dementia, Opioid Use Disorder, Schizophrenia, Seizures

Studies at this site

• A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) — Running, not enrolling
• A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy — Stopped early
• An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures — Stopped early
• A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia — Completed
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia — Completed
• Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing — Completed
• A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures — Completed